NCT07470177

A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults

A Single-center, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Effect of a Single-dose of JMKX003142 on QTc Intervals in Healthy Participants

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Jemincare · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants

Conditions

• ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Interventions

Type	Name	Description
DRUG	JMKX003142 tablets	Participants will receive single of JMKX003142 6mg
DRUG	JMKX003142 tablets	Participants will receive single of JMKX003142 30mg
DRUG	Placebo	Participants will receive single of Placebo

Timeline

• Start date: 2026-03-27
• Primary completion: 2026-05-14
• Completion: 2026-06-23
• First posted: 2026-03-13
• Last updated: 2026-03-13